These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 21829020

  • 1. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
    Kudo M.
    Dig Dis; 2011; 29(3):289-302. PubMed ID: 21829020
    [Abstract] [Full Text] [Related]

  • 2. Targeted therapy for liver cancer: updated review in 2012.
    Kudo M.
    Curr Cancer Drug Targets; 2012 Nov 01; 12(9):1062-72. PubMed ID: 22920326
    [Abstract] [Full Text] [Related]

  • 3. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX.
    Expert Opin Investig Drugs; 2010 May 01; 19(5):663-72. PubMed ID: 20367287
    [Abstract] [Full Text] [Related]

  • 4. Systemic treatment of hepatocellular carcinoma: dawn of a new era?
    Zhu AX.
    Ann Surg Oncol; 2010 May 01; 17(5):1247-56. PubMed ID: 20405329
    [Abstract] [Full Text] [Related]

  • 5. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M, Ueshima K.
    Oncology; 2010 Jul 01; 78 Suppl 1():154-66. PubMed ID: 20616599
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
    Kim HY, Park JW.
    Dig Dis; 2011 Jul 01; 29(3):303-9. PubMed ID: 21829021
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
    Lee JM, Han KH.
    Oncology; 2010 Jul 01; 78 Suppl 1():167-71. PubMed ID: 20616600
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
    Kuzuya T, Tsuchiya K, Izumi N.
    Gan To Kagaku Ryoho; 2010 Oct 01; 37(10):1883-86. PubMed ID: 21069944
    [No Abstract] [Full Text] [Related]

  • 11. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 Oct 01; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Novel molecular therapies in hepatocellular carcinoma.
    Faivre S, Bouattour M, Raymond E.
    Liver Int; 2011 Jan 01; 31 Suppl 1():151-60. PubMed ID: 21205154
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
    Zender L, Kubicka S.
    Onkologie; 2008 Oct 01; 31(10):550-5. PubMed ID: 18854656
    [Abstract] [Full Text] [Related]

  • 18. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.
    Kudo M.
    Dig Dis; 2011 Oct 01; 29(3):273-7. PubMed ID: 21829017
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.